Blarcamesine is a new class of drug seeking approval in AD without the requisite confirmatory trial data. So while your contention and Boi’s might be right - out of the customary 2 x P3 trials seeking to prove it both are missing. Instead of getting at least one of them going, Missling has waste over 3 years trying to make do with a too small and short P2b trial.
Market Data 
Markets 
AI
